Home » EPIC Archives: IMM

IMM News Archives

Q&A with Tim McCarthy Non-Executive Chairman at ImmuPharma PLC (LON:IMM)

Immupharma Plc

ImmuPharma's Tim McCarthy discusses their Phase III Lupuzor trial; why the completion of patient recruitment on track is important, the significance of the 70 patients dosed in the US, safety profile and its importance, the market potential for Lupuzor if approved and their key milestones for 2017/2018 in this exclusive interview with DirectorsTalk

Read Article »